
By Sneha S K and Sahil Pandey
Dec 31 (Reuters) - The U.S. Food and Drug Administration has declined to approve Corcept Therapeutics' drug for the treatment of a rare hormonal disorder, the company said on Wednesday.
Shares of the drugmaker were down 48% at $36.41.
The company said the FDA could not arrive at a favorable benefit-risk assessment for the hormone-blocking oral treatment, known as relacorilant, without Corcept providing additional evidence of effectiveness.
The company was seeking approval for relacorilant as a treatment for patients with hypertension secondary to hypercortisolism.
"FDA's request for additional data may require additional trials, significantly dimming Corcept's outlook in Cushings," said Truist analyst Joon Lee.
Hypercortisolism, also known as Cushing's syndrome, occurs when the body is exposed to high cortisol activity.
Corcept had submitted trial data that showed that relacorilant made improvements in a wide array of hypercortisolism's signs and symptoms.
"We will meet with the FDA as soon as possible to discuss the best path forward," said Joseph Belanoff, Corcept's CEO.
Main symptoms of hypercortisolism include a fatty hump between the shoulders, a rounded face, and pink or purple stretch marks on the skin. People with Cushing's also experience diabetes, high blood pressure, muscle weakness and immune suppression.
Relacorilant is a selective cortisol modulator designed to block the effects of cortisol, while avoiding certain off‑target hormonal effects.
"Given the company had opportunities to address FDA's concerns during mid and late-stage reviews, it's unclear if any further dialogue can resolve the review issues without additional trials," Lee added.
Corcept is also studying the drug in a variety of serious disorders including ovarian and prostate cancer. Its other drug known as Korlym is approved to treat high blood sugar caused by hypercortisolism in adults with endogenous Cushing's syndrome.
Other approved treatments for Cushing's syndrome include Isturisa by Recordati and Xeris Biopharma's Recorlev.
(Reporting by Sahil Pandey and Sneha S K in Bengaluru; Editing by Shailesh Kuber)
latest_posts
- 1
Kansas school officials report high student illness, dismiss early - 2
Two reportedly killed as Israel attacks Hezbollah targets in Lebanon - 3
Lilly becomes first healthcare firm to join trillion-dollar club, Wall Street reacts - 4
Manual for Tracking down the Nearby Business sectors and Marketplaces - 5
Embrace the Outside: Exercises and Entertainment
Polish law aimed at lowering petrol prices takes effect
IDF carried out mission to locate former hostage Avera Mengistu a day before Oct. 7
New York to require social media platforms to display mental health warnings
Most loved Occasion Dish: What Makes Your Merry Table?
Golan resident convicted of spying for Iran after passing tank movement, missile-impact data
6 Well known Ladies' Fragrances On the planet
Space Condos to Lift Your Metropolitan Living
Artemis will take Americans to the moon for the 1st time since 1972. Why has it been so hard to go back?
Overlooked infertility care should be part of national health services, says WHO













